NDA (New Drug Application)
ANDA (Generic Application)
Track protection status across key markets to assess launch feasibility.
It is formulated by 3 pharmaceutical companies such as ACADIA PHARMS INC, MSN, ZYDUS. It is marketed under 2 brand names, including NUPLAZID, PIMAVANSERIN. Available in 3 different strengths, such as EQ 17MG BASE, EQ 34MG BASE, EQ 10MG BASE, and administered through 2 routes including TABLET;ORAL, CAPSULE;ORAL.
API availability: Loading API feasibility...
Licensing: 3 potential partnersUS Launch window: Loading launch window...
Stay ahead with worldwide patent expiry and latest updates.
FDA approval history for this ingredient
Stay ahead with worldwide patent expiry insights, exclusivity data, and latest updates.
Key expiration dates for US patents covering this ingredient
Stay ahead with worldwide patent expiry insights, market data, and research updates.
Latest drug strengths approved by FDA
| Strength | Route of Administration | Companies | Latest Approval Date |
|---|
Patents approved by the FDA for the ingredient
|
|
Patent Number | Publication Date | Legal Status | Patent Expiry Date | |
|---|---|---|---|---|---|
| {"application_id":"1461","ingredient":"PIMAVANSERIN TARTRATE","trade_name":"NUPLAZID","family_id":"b2824ed827e740b39fc1","publication_number":"US7923564B2","cleaned_patent_number":"7923564","drug_product_flag":"Y","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2025-09-26","publication_date":"2011-04-12","legal_status":"Granted"} | US7923564B2 Molecular Formulation | 12 Apr, 2011 | Granted | 26 Sep, 2025 | |
| {"application_id":"1459","ingredient":"PIMAVANSERIN TARTRATE","trade_name":"NUPLAZID","family_id":"ed3981de16b94b4ca84b","publication_number":"US7659285B2","cleaned_patent_number":"7659285","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2026-08-24","publication_date":"2010-02-09","legal_status":"Granted"} | US7659285B2 | 09 Feb, 2010 | Granted | 24 Aug, 2026 | |
| {"application_id":"1460","ingredient":"PIMAVANSERIN TARTRATE","trade_name":"NUPLAZID","family_id":"b2824ed827e740b39fc1","publication_number":"US7732615B2","cleaned_patent_number":"7732615","drug_product_flag":"Y","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2028-06-03","publication_date":"2010-06-08","legal_status":"Granted"} | US7732615B2 Molecular Formulation | 08 Jun, 2010 | Granted | 03 Jun, 2028 | |
| {"application_id":"24037","ingredient":"PIMAVANSERIN TARTRATE","trade_name":"NUPLAZID","family_id":"ed3981de16b94b4ca84b","publication_number":"US7601740B2","cleaned_patent_number":"7601740","drug_product_flag":"Y","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2030-04-29","publication_date":"2009-10-13","legal_status":"Granted"} | US7601740B2 Molecular Formulation | 13 Oct, 2009 | Granted | 29 Apr, 2030 | |
| {"application_id":"42314","ingredient":"PIMAVANSERIN TARTRATE","trade_name":"NUPLAZID","family_id":"a34a4a8f33a74a55a900","publication_number":"US10953000B2","cleaned_patent_number":"10953000","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2037-03-23","publication_date":"2021-03-23","legal_status":"Granted"} | US10953000B2 | 23 Mar, 2021 | Granted | 23 Mar, 2037 | |
| {"application_id":"42313","ingredient":"PIMAVANSERIN TARTRATE","trade_name":"NUPLAZID","family_id":"a34a4a8f33a74a55a900","publication_number":"US10517860B2","cleaned_patent_number":"10517860","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2037-03-23","publication_date":"2019-12-31","legal_status":"Granted"} | US10517860B2 | 31 Dec, 2019 | Granted | 23 Mar, 2037 | |
| {"application_id":"39709","ingredient":"PIMAVANSERIN TARTRATE","trade_name":"NUPLAZID","family_id":"e38902854e1f484aaedf","publication_number":"US11452721B2","cleaned_patent_number":"11452721","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2038-08-27","publication_date":"2022-09-27","legal_status":"Granted"} | US11452721B2 Formulation | 27 Sep, 2022 | Granted | 27 Aug, 2038 | |
| {"application_id":"39706","ingredient":"PIMAVANSERIN TARTRATE","trade_name":"NUPLAZID","family_id":"e38902854e1f484aaedf","publication_number":"US10646480B2","cleaned_patent_number":"10646480","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2038-08-27","publication_date":"2020-05-12","legal_status":"Granted"} | US10646480B2 Formulation | 12 May, 2020 | Granted | 27 Aug, 2038 | |
| {"application_id":"39703","ingredient":"PIMAVANSERIN TARTRATE","trade_name":"NUPLAZID","family_id":"e38902854e1f484aaedf","publication_number":"US10849891B2","cleaned_patent_number":"10849891","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2038-08-27","publication_date":"2020-12-01","legal_status":"Granted"} | US10849891B2 Formulation | 01 Dec, 2020 | Granted | 27 Aug, 2038 | |
| {"application_id":"39705","ingredient":"PIMAVANSERIN TARTRATE","trade_name":"NUPLAZID","family_id":"e38902854e1f484aaedf","publication_number":"US10449185B2","cleaned_patent_number":"10449185","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2038-08-27","publication_date":"2019-10-22","legal_status":"Granted"} | US10449185B2 Formulation | 22 Oct, 2019 | Granted | 27 Aug, 2038 |
Latest clinical trials and research studies for this ingredient
| NCT ID | Title | Status | Phase | Conditions | Start Date | Completion Date |
|---|
Manufacturing Locations
Unlock access to all suppliers of Pimavanserin Tartrate
Note: Patent expirations and exclusivity timelines are dynamic and may shift based on litigation, regulatory extensions, and maintenance filings. Regular monitoring is advised.